Quick Recap
Infectious Diseases System, Protocol 6/6 — completing the Infectious Diseases System.
1. Scope
Covers influenza and SARS-CoV-2 (COVID-19) as the two most ICU-relevant severe viral pneumonias with established antiviral/immunomodulatory evidence bases. Other respiratory viral pathogens (RSV, rhinovirus/enterovirus, other coronaviruses, metapneumovirus, parainfluenza, adenovirus) are managed primarily with supportive care given the absence of specific antiviral therapy for most of these in critically ill adults. Clinical manifestations span asymptomatic infection to ARDS, septic shock, COPD/asthma exacerbation, ADHF, thromboembolism, and bacterial/fungal superinfection — always consider secondary complications, not just the primary viral process.
2. Preventive and Infection Control Measures
Mode of transmission dictates precaution type (droplet, contact, and/or airborne) — apply consistently during ALL patient care activities, with particular attention to aerosol-generating procedures (e.g., bronchoscopy), where enhanced precautions are essential. Hand hygiene and environmental decontamination remain foundational. Vaccination remains the most effective prevention strategy — screen ICU patients for vaccine eligibility and consider administration at clinical improvement or transitions of care (routine ICU-phase vaccination itself remains a lower-priority/controversial practice given concerns about immune dysregulation/adverse reactions during acute critical illness).
3. Supportive Care (Foundation of Management Regardless of Specific Virus)
Antipyretics, bronchodilators as needed, electrolyte/fluid management, VTE prophylaxis, sleep hygiene, oxygen/NIV/invasive mechanical ventilation per standard respiratory failure principles (see Acute Respiratory Failure and ARDS protocols, Respiratory System), ECMO for refractory cases per ARDS protocol criteria. Evidence for many specific supportive measures is limited/mixed — individualize based on clinical trajectory rather than applying a fixed bundle uniformly.
4. Influenza — Antiviral Therapy
Oseltamivir (neuraminidase inhibitor) is the mainstay of treatment for critically ill influenza A/B pneumonia. Early administration (within 48 hours of symptom onset) is recommended and associated with improved outcomes, consistent with its mechanism — strongly consider oseltamivir for ALL patients presenting with influenza pneumonia, particularly early in the disease course; a lower threshold to empirically treat/suspect influenza is appropriate during seasonal epidemics.
Current data do NOT support routine high-dose (150mg) or extended-duration (10 days) oseltamivir, or a test-driven duration strategy, in general critical illness — BUT severely ill or highly immunosuppressed patients are a population of specific interest where combination therapy (baloxavir + oseltamivir/peramivir) or extended duration may be considered.
Peramivir (IV): reasonable alternative when enteral oseltamivir absorption is a concern (e.g., ileus, high-grade GI dysfunction).
Baloxavir (cap-dependent endonuclease inhibitor): consider for documented NAI allergy/intolerance or suspected NAI resistance; efficacy data in hospitalized patients remain limited.
Zanamivir: CONTRAINDICATED in patients with underlying airway disease (asthma/COPD) given bronchospasm risk — avoid in AECOPD/asthma-associated influenza specifically (cross-reference: the COPD protocol notes oseltamivir is recommended regardless of symptom duration in AECOPD, but zanamivir is explicitly contraindicated there).
Amantadine/rimantadine (M2 ion channel inhibitors): NOT RECOMMENDED — no influenza B activity and >90% resistance rates — essentially obsolete for current clinical use.
Corticosteroids: routine use is NOT recommended for influenza pneumonia given lack of high-quality supporting data, combined with mixed observational evidence associating steroid use with WORSE outcomes, resistance development, and superinfection — a notable contrast with the strong, guideline-level steroid recommendation for COVID-19 (Section 5); weigh steroid use in influenza carefully against other compelling indications (e.g., concurrent adrenal insufficiency, COPD exacerbation) rather than using it reflexively for the viral pneumonia itself.
Other adjunctive therapies (macrolides, COX-2 inhibitors, mTOR inhibitors, statins, vitamin C, IVIG, nitazoxanide): NOT supported by current evidence — do not add these as routine adjuncts.
5. COVID-19 — Antiviral and Immunomodulatory Therapy
Guidance in this area evolves rapidly — always cross-check against current NIH/IDSA treatment guidelines given the pace of change; the framework below reflects the evidence synthesis at time of writing.
Corticosteroids (dexamethasone) are the CORNERSTONE of management for hospitalized COVID-19 patients requiring ANY supplemental oxygen — multiple RCTs demonstrate improved outcomes and reduced mortality; rates of secondary infection/serious adverse events have NOT been consistently elevated with routine use, unlike the influenza steroid caution above. Dexamethasone 6mg IV/PO/enteral daily, typically up to 10 days or until discharge.
Remdesivir (RNA polymerase inhibitor): 200mg IV loading, then 100mg IV daily, typically 5 days or until discharge. Most effective EARLY in the disease course (like influenza antivirals). Consider adding to dexamethasone particularly for patients on conventional or high-flow oxygen — this combination was common in trials showing improved outcomes. In patients requiring invasive mechanical ventilation or ECMO, remdesivir may provide LIMITED OR NO clinical benefit, but may still be considered in immunocompromised patients, those with evidence of ongoing viral replication, or within 10 days of symptom onset — weigh risks/benefits individually rather than applying uniformly across severity tiers. Caution with renal dysfunction given the sulfobutylether beta-cyclodextrin excipient, though post hoc/observational data suggest reasonable safety if benefit is felt to outweigh risk.
Second immunomodulator (added to dexamethasone) — IL-6 or JAK inhibitor:
Agent | Class | Dosing |
Tocilizumab | IL-6 inhibitor | 8 mg/kg IV once (max 800mg) |
Sarilumab | IL-6 inhibitor (alternative to tocilizumab) | 200-400mg IV once |
Baricitinib | JAK1/JAK2 inhibitor | 1-4mg PO/enteral daily, up to 14 days |
Tofacitinib | JAK1/JAK3 inhibitor (alternative to baricitinib) | 5-10mg PO/enteral BID |
No high-quality head-to-head comparative trials exist between these agents — providers may prefer tocilizumab or baricitinib given more robust evidence/experience in ICU patients specifically. Trials support use in patients on NIV/invasive ventilation and/or with elevated inflammatory markers (ferritin, CRP), though immunosuppressed patients and those with other active infections were UNDERREPRESENTED in these trials — cautious use, if any, of IL-6/JAK inhibitors is recommended in these populations; remdesivir may be a preferable alternative in this specific subgroup given the infection-risk profile of IL-6/JAK blockade. Data are mixed but generally show improved outcomes when adding a SECOND immunomodulator to dexamethasone, without a consistent significant safety signal, supporting routine consideration of this combination in ICU-level COVID-19.
SARS-CoV-2-specific monoclonal antibodies: insufficient data to recommend routine use in hospitalized patients at time of writing — verify current status given rapid evidence evolution and viral variant drift affecting monoclonal efficacy.
Anticoagulation in COVID-19 — severity-stratified, NOT one-size-fits-all:
- Empiric THERAPEUTIC anticoagulation in critically ill patients on high-flow, NIV, or invasive mechanical ventilation WITHOUT a known VTE or other clear indication is NOT recommended — available data show no improvement in hard outcomes vs standard VTE prophylaxis in this sicker subgroup
- Patients requiring only CONVENTIONAL (low-flow) oxygen therapy: randomized data show SIGNIFICANT improvement in various outcomes with therapeutic anticoagulation vs standard prophylaxis — a genuinely different recommendation for this less-sick oxygen-requiring subgroup, reflecting a severity-dependent treatment effect rather than a uniform anticoagulation strategy across all COVID-19 severity
- Weigh this against bleeding risk carefully even in the conventional-oxygen subgroup where benefit is shown
- If a known/identified VTE (or other clear indication) exists: initiate standard therapeutic anticoagulation regardless of oxygen requirement tier
- Elevated D-dimer with low bleeding risk: therapeutic anticoagulation without a confirmed VTE indication may be considered case-by-case, though this is not a blanket recommendation
6. Immediate Stabilization (ABCDE) — Shared Principles
Standard hypoxemic respiratory failure approach (see Acute Respiratory Failure protocol) applies to both influenza and COVID-19 severe pneumonia; ARDS management principles (lung-protective ventilation, proning for P/F <150, judicious PEEP titration) apply equally once ARDS develops from either etiology (see ARDS protocol).
Checklist:
7. Investigations
Multiplex respiratory viral PCR panel, influenza-specific rapid antigen/PCR, SARS-CoV-2 PCR/antigen, CXR/CT chest, inflammatory markers (ferritin, CRP — relevant to COVID-19 immunomodulator decision-making), D-dimer (COVID-19 anticoagulation decision-making), bacterial/fungal co-infection workup if deteriorating despite appropriate antiviral/supportive therapy, renal function (remdesivir dosing consideration).
8. Organ Support
Lung-protective mechanical ventilation and ARDS-specific rescue therapies (proning, ECMO) per the ARDS protocol; standard septic shock support if superinfection/shock develops; VTE prophylaxis (or therapeutic anticoagulation per the severity-stratified COVID-19 criteria above); standard ICU supportive care.
9. Consultation Matrix
Consultation | Trigger | Timing |
Infectious Disease | Severe/complicated viral pneumonia, immunosuppressed host, antiviral resistance concern | Immediate |
Pulmonology/Critical Care | ARDS, ECMO candidacy | Immediate for severe hypoxemic failure |
10. Monitoring Framework
Serial oxygenation trend (P/F ratio), inflammatory marker trend if using immunomodulators, renal function (remdesivir), watch for secondary bacterial/fungal superinfection with clinical deterioration after initial stabilization, D-dimer/VTE surveillance.
11. Complications
ARDS, septic shock (viral or superimposed bacterial/fungal), VTE (particularly COVID-19-associated coagulopathy), secondary bacterial/fungal pneumonia, ADHF exacerbation, post-acute sequelae ("long COVID"/PACS — an emerging, still-being-characterized long-term complication). Prevention: early antiviral therapy, appropriate infection control to prevent nosocomial spread, severity-stratified anticoagulation strategy, judicious immunomodulator use with infection-risk awareness. Rescue: standard ARDS/septic shock rescue therapies, escalating antimicrobial coverage for confirmed superinfection.
12. Escalation & De-escalation
Escalate: worsening hypoxemia/ARDS -> full ARDS protocol escalation (proning, consider NMB, ECMO evaluation); clinical deterioration after initial improvement -> evaluate for bacterial/fungal superinfection.
De-escalate: improving oxygenation, completing antiviral/immunomodulator course, no evidence of superinfection -> wean respiratory support, discontinue isolation per infection control guidance once criteria met, transition to standard ward-level care.
13. ICU Discharge Criteria
Respiratory status stable/improving, antiviral course completed, immunomodulator course completed (COVID-19) with no evidence of resultant infectious complication, anticoagulation strategy finalized appropriately, no evidence of ongoing untreated superinfection, isolation precautions discontinued per current infection control criteria.
14. Documentation & Medicolegal Checklist
15. Key Guidelines
COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health (continuously updated — verify current version at time of use). Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the IDSA: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019;68(6):e1-e47.
16. Controversies
COVID-19 treatment guidance evolves rapidly given the ongoing evolution/mutation of SARS-CoV-2 and continued accumulation of trial evidence — the specific agents, dosing, and severity-stratified recommendations in this protocol should be actively cross-checked against current NIH/IDSA guidelines rather than treated as static. The role of SARS-CoV-2-specific monoclonal antibodies remains unsettled and highly variant-dependent. Comparative superiority between IL-6 and JAK inhibitors as the "second immunomodulator" for COVID-19 has not been established by head-to-head trials. The precise anticoagulation strategy in COVID-19 patients with elevated D-dimer but no confirmed VTE remains a case-by-case judgment rather than a guideline-mandated approach.
17. References
- Viral Pneumonia (Influenza and SARS-CoV-2 sections). Washington Manual of Critical Care, 4th ed, 2025 (Ch. 46).
- COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/ (continuously updated).
- Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the IDSA: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019;68(6):e1-e47.
- Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med. 2020;46:315-328.
- RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693-704.
See also: Acute Respiratory Failure, ARDS, Severe Pneumonia, COPD Exacerbation (Respiratory System) for the shared respiratory failure and secondary bacterial pneumonia management frameworks.